STELLARA Clinical Intervention and Patient Monitoring software, powered by the TheraDoc Expert System Platform, showed a significant cost savings and reduction of adverse drug events (ADEs) at Franciscan Health System (FHS), according to a 6-month study completed at the Tacoma, Wash-based health system. From July 2004 to June 2005, FHS pharmacy management tracked the number of medication orders and the staff's productivity for 6 months prior to STELLARA's implementation, compared with the first 6 months post-implementation.
"We have experienced tremendous success with STELLARA as our intelligent interface software over the past year, which led to an increase in clinical interventions by our pharmacists," said J. Kelly Martin, PharmD, director of pharmaceutical services at FHS. "We are seeing concrete results in the forms of cost savings and improved patient care. In 2005, cost savings from interventions increased by 23%, and our pharmacists prevented 222 ADEs (a 23% increase from 2004) after implementation of STELLARA. Interventions made by pharmacists increased from 17,906 to 27,667a 55% increase."
Manufactured by bioMérieux Inc, the STELLARA system provides knowledgeenriched, infectious disease-specific recommendations to clinicians for medication treatment management. The company recently completed its suite of Intelligent Patient Therapy Software Systems, allowing the clinician to capture a more thorough view of the patient, preventing potential medication errors, and decreasing the chances of costly ADEs.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs